ZeroEyes Launches Pilot Program with Modesto Police Department to Enhance Public Safety
ZeroEyes, the creators of the only AI-based gun detection video analytics platform that holds the full U.S. Department of Homeland Security SAFETY Act Designation, today announced that its proactive gun detection and intelligent situational awareness platform has been deployed by the Modesto Police Department (PD) in strategic locations throughout the city. This partnership reflects the Modesto Police Department's commitment to utilizing the latest tools to improve public safety and reduce crime in the community.
'We want our community members to feel secure in their work, leisure, and daily lives,' said Cat McFadon, Police Civilian Manager of Modesto PD. 'ZeroEyes' ability to detect firearms and trigger instant alerts will allow us to respond more quickly and efficiently to gun-related threats. With this additional technology in our toolbelt, we're reinforcing our efforts to drive down crime and make Modesto a safer place for everyone.'
Modesto, a city of 216,000 residents in Northern California, is known for its progressive law enforcement efforts. The department has a long-standing dedication to equipping its officers with the most advanced technology to support their mission to protect life and property. This pilot program is intended to assess the effectiveness of ZeroEyes technology in real-world conditions, with the goal of expanding its use in key areas such as local schools and the city's shopping mall.
ZeroEyes' AI gun detection and intelligent situational awareness software layers onto existing digital security cameras. If a gun is identified, images are instantly shared with the ZeroEyes Operations Center (ZOC), the industry's only U.S.-based, fully in-house operation center, which is staffed 24/7/365 by specially trained military and law enforcement veterans. If these experts determine that the threat is valid, they dispatch alerts and actionable intelligence — including visual description, gun type, and last known location — to Modesto PD as quickly as 3 to 5 seconds from detection.
'The Modesto PD's commitment to increasing public safety through innovative technology aligns perfectly with our mission, and we look forward to the collaboration,' said Mike Lahiff, CEO of ZeroEyes. 'We're confident that ZeroEyes will not only meet but exceed Modesto PD's expectations, enhancing response times and reducing the impact of gun-related threats.'
About ZeroEyes
ZeroEyes delivers a proactive, human-verified AI gun detection software solution that integrates into existing digital security cameras and helps to mitigate mass shootings and gun-related violence by reducing response times, providing actionable intelligence with images, and delivering clarity among chaos — ultimately saving lives. ZeroEyes' patented solution has been recognized by the U.S. Department of Homeland Security (DHS) as a promising anti-terrorism technology and is the first video analytics technology to receive full SAFETY Act DT&E Designation.
Founded by Navy SEALs and elite technologists, ZeroEyes dispatches accurate and real-time actionable intelligence about the illegal brandishing of a gun near or in an occupied area or building, to local staff and law enforcement with an image of the shooter(s) and location of the threat, as quickly as 3 to 5 seconds from the moment the gun is detected.
The ZeroEyes team also provides tech consulting, installation assistance and practice drills for active shooter events to enhance safety at schools, corporate and government facilities. Headquartered in the Greater Philadelphia area, the company's affordable and effective gun detection solution has been adopted by the US Department of Defense, leading public K-12 school districts, colleges/universities, healthcare facilities, commercial property groups, manufacturing plants, Fortune 500 corporate campuses, shopping malls, big-box retail stores and more. Learn more about ZeroEyes at ZeroEyes.co m.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 days ago
- Business Insider
Iovance Amtagvi receives Health Canada approval for advanced melanoma
Iovance Biotherapeutics (IOVA) announced Health Canada has issued a notice of compliance with conditions for Amtagvi, a tumor-derived autologous T cell immunotherapy. Amtagvi is indicated for the treatment of adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy including a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor, and who have no satisfactory alternative treatment options. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Business Wire
6 days ago
- Business Wire
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the three months ended June 30, 2025, as well as key recent clinical and corporate developments. 'Commercial and regulatory momentum for Multikine is accelerating due to three driving factors—our partnership negotiations in Saudi Arabia, the increasing interest in CEL-SCI from investors in the Middle East, and continued recognition in the global scientific and regulatory community that PD-L1 is a valuable predictive marker for head and neck cancer,' stated CEL-SCI CEO, Geert Kersten. 'We are particularly encouraged about the potential for Multikine to become commercially available in Saudi Arabia in 2025. Should this happen, we believe it could support our regulatory and commercial efforts worldwide.' Corporate and Clinical Developments include: CEL-SCI's CEO and a Director of the Company each purchased a combined total of 32,116 shares of restricted common CEL-SCI stock in July 2025. Gross proceeds of approximately $5.7 million were raised by CEL-SCI in July 2025 through the sale of 1,500,000 shares of common stock at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. In May of 2025, the Company raised gross proceeds of $5 million through the sale of 2,000,000 shares of common stock priced at $2.50 per share. CEL-SCI is set to sign a commercialization and regulatory partnership agreement with a leading Saudi Arabian pharmaceutical company for Multikine* (Leukocyte Interleukin, Injection) in the treatment of head and neck cancer in the Kingdom of Saudi Arabia. A Breakthrough Medicine Designation application for Multikine was filed by the pharma partner with the Saudi Food and Drug Authority (SFDA). According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days. Following the granting of the Breakthrough Medicine Designation, Multikine would immediately become available for patient access and reimbursement/sale in Saudi Arabia. Several leading Saudi funds have expressed interest in investing in CEL-SCI, Multikine and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market. CEL-SCI's offering with Multikine is in line with Saudi Arabia's Vision 2030 initiative which seeks to make the Kingdom a global biotech hub. Given the SFDA's 60-day timeline to make Multikine potentially available, in-country investors have expressed interest in bringing a much-needed cancer treatment to market while also supporting their nation's health-tech goals. A new study supports CEL-SCI's strategy to seek early approval in the U.S. CEL-SCI is in final preparations before starting enrollment of its 212-patient Confirmatory Registration Study for Multikine in newly diagnosed locally advanced head and neck cancer patients. The U.S. Food and Drug Administration (FDA) has given CEL-SCI the go-ahead for the study. CEL-SCI plans to seek early approval based on early tumor responses. A third-party study recently published in Cancer Cell titled 'Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies' provides support for CEL-SCI's approach. The concept that tumor responses predict survival has been acknowledged for many cancer types and has led to accelerated approval of many cancer drugs. The third-party study published in Cancer Cell gives further support that this is also true in the neoadjuvant pre-surgical immunotherapy treatment of head and neck cancer. More data on PD-L1 as a predictive biomarker signals a clear regulatory pathway for Multikine in PLD-L1 negative patients. There is a growing body of data on PD-L1 as a predictive biomarker and diagnostic for cancer. In June, the FDA approved Merck's KEYTRUDA® (pembrolizumab), an anti-PD-L1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1. Of note, the FDA granted Merck priority review in February 2025 and approval in June 2025 based on interim results. This sets a positive precedent for Multikine in PD-L1 low and negative patients. Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk of recurrence and progression (EFS) by only 30% compared with standard of care in patients whose tumors expressed higher PD-L1 without demonstrating improvement in overall survival. Financial Results During the three months ended June 30, 2025, net loss available to common shareholders was $5.7 million compared to $7.5 million in the prior year period. Basic and diluted net loss per common share was $1.36 for the three months ended June 30, 2025, compared to $4.18 for the three months ended June 30, 2024. In demonstration of his deep commitment to the Company and Multikine's potential to significantly improve patient outcomes, CEO Geert Kersten has been and is currently working without taking a salary. About CEL-SCI Corporation CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor before surgery, radiation and chemotherapy because that is the time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. Based on the data from the completed randomized controlled Phase 3 study of 928 patients, the FDA concurred with CEL-SCI's target patient selection criteria and gave the go-ahead to conduct a confirmatory Registration Study which will enroll 212 patients. CEL-SCI will enroll newly diagnosed locally advanced not yet treated resectable head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy), representing about 100,000 patients annually. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2024. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. * Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
Business Wire
6 days ago
- Business Wire
BioFlyte Awarded U.S. Department of Homeland Security SAFETY Act Designation for Qualified Anti-Terrorism Technology
ALBUQUERQUE, N.M.--(BUSINESS WIRE)-- BioFlyte, a chemical and bioaerosol surveillance firm with a disruptive new class of fieldable chemical and biological threat collection, detection, and identification solutions, today announced that the U.S. Department of Homeland Security (DHS) has awarded the company a SAFETY Act Designation for its aerosol chem/biothreat detection and identification technology. This recognition as a Qualified Anti-Terrorism Technology (QATT) underscores the proven effectiveness and reliability of BioFlyte's solutions in detecting and mitigating airborne chemical and biological threats, while providing important liability protections under the Support Anti-terrorism by Fostering Effective Technologies (SAFETY) Act of 2002. This recognition as a Qualified Anti-Terrorism Technology (QATT) underscores the proven effectiveness and reliability of BioFlyte's solutions in detecting and mitigating airborne chemical and biological threats. Share The SAFETY Act Designation affirms that BioFlyte's technology meets DHS's rigorous evaluation criteria, including high performance reliability, consistent positive operational results, and adherence to disciplined, documented processes. As part of the Designation, the company's liability, and that of its customers, is limited to the level of insurance coverage required by DHS for Designated Technologies in the event of a terrorist-driven incident. "We are honored to receive the DHS SAFETY Act Designation, which not only validates the strength and dependability of our technology but also provides meaningful protections for our customers," said Todd Sickles, CEO of BioFlyte. "This achievement reflects DHS' confidence in the reliability, predictability and consistent performance of our technology and it further differentiates BioFlyte in the marketplace." Many of BioFlyte's customer prospects have expressed strong interest in this certification, which is held by few competitors in the industry. The designation recognizes that BioFlyte's technology: Performs as intended with high confidence in continued effectiveness Produces consistent positive results with low failure and false alarm rates Meets or exceeds performance specifications Operates with proven installation, maintenance, and training procedures Adheres to documented quality standards and effective QA/QC processes This milestone follows on the heels of BioFlyte's recent U.S. Air Force SBIR Phase I award earlier this year, marking another significant step in the growing adoption of the company's technology in homeland security and public safety applications. "BioFlyte's BioTOF™ product empowers our customers with the game-changing ability to detect chemical and biological aerosols at the same time, in real-world conditions,' said Wayne Bryden Ph.D., Chief Science Officer at BioFlyte. 'With its dynamic threat library, BioTOF not only identifies emerging hazards on the spot but also captures and stores them for future defense, keeping our customers a decisive step ahead." About BioFlyte BioFlyte is a chem/bioaerosol surveillance company that is commercializing a revolutionary new class of fieldable chemical and biological contamination sampling, detection, and identification solutions. The firm's current market focus is critical infrastructure protection and mail screening in both the government and commercial sectors. For more information about BioFlyte and its products, please visit:
